These findings complement each other and together indicate that mutant KRAS lies at the heart of tumor immune evasion, with oncogenic KRAS signaling functioning as a 2-pronged approach to restrict the antitumor potential of both innate and adaptive immune systems. The gene discussed is KRAS; the disease is neoplasm.